TY - JOUR T1 - Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3<sup>+</sup>Tregs JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00751-2020 VL - 57 IS - 1 SP - 2000751 AU - Jacobo López-Abente AU - Cristina Benito-Villalvilla AU - Xavier Jaumont AU - Pascal Pfister AU - Paolo Tassinari AU - Oscar Palomares Y1 - 2021/01/01 UR - http://erj.ersjournals.com/content/57/1/2000751.abstract N2 - Allergic sensitisation and viral respiratory tract infections represent the main risk factors for asthma development and severity. IgE plays a key role in the pathophysiology of allergic asthma and allergic multimorbidities [1, 2]. Omalizumab, a recombinant humanised monoclonal antibody against IgE, has been used to treat allergic asthma in children and adults for many years [3–5]. Omalizumab restores the capacity of human plasmacytoid dendritic cells (pDCs) to produce interferon (IFN)-α, increasing their antiviral activity and reducing viral-induced asthma exacerbations [6, 7]. pDCs prime T-helper cell (Th)1 or Th2 responses depending on the encountered antigens.IgE-FcεR1 cross-linking on human pDCs impairs their capacity to generate regulatory T-cells and in vitro omalizumab restores this ability. These findings may pave the way for novel biomarkers to assess omalizumab clinical efficacy and responder patients. https://bit.ly/2ZQbJ9tWe thank the fluorescence microscopy and flow cytometry core unit at UCM for excellent assistance with flow cytometry assays. We thank Silvia Sanchez-Ramón (Hospital Clínico San Carlos, Madrid, Spain) for providing the intravenous IgG (Privigen, CSL Behring). ER -